Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia
Annals of Hematology · 28.07.2026 · 105 (11)
DOI: 10.1007/s00277-026-07196-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 28.07.2026. Verfasst von Hidetoshi Irifune und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu-shi, Fukuoka, 802-8561, Japan. hidetoshi_irif…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Fusion Proteins, bcr-abl. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Emergence of BCR::ABL1 during FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy is a rare resistance mechanism in acute myeloid leukemia (AML). We report a case of relapsed AML with sequential clonal evolution after allogeneic hematopoietic stem cell transplantation (allo-HSCT). A previously healthy man in his 30s was diagnosed with AML with maturation; initial cytogenetics were normal, and both FLT3 -internal tandem duplication ( FLT3- ITD) and BCR::ABL1 were absent, while targeted sequencing identified an FBXW7 mutation. After induction failure, he underwent allo-HSCT. At post-transplant relapse during venetoclax plus azacitidine maintenance, FLT3- ITD and WT1 mutations newly emerged. Quizartinib induced remission, but a second relapse occurred with emergence of BCR::ABL1 while FLT3- ITD persisted. Cytogenetics showed t(9;22)(q34;q11), and FISH confirmed BCR::ABL1 fusion in 73% of bone marrow cells, with the minor transcript (p190) confirmed by quantitative PCR. Despite no ABL1 kinase domain mutations, imatinib and ponatinib failed to control the disease. These findings suggest that BCR::ABL1 emergence may represent a bypass resistance mechanism arising under quizartinib-associated selective pressure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu-shi, Fukuoka, 802-8561, Japan. hidetoshi_irifune01@kitakyu-cho.jp.
- Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
- Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
- Department of Hematology, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu-shi, Fukuoka, 802-8561, Japan.
Zitieren
APA
Irifune, H., Semba, Y., Uehara, Y., Ohta, T., Sugio, Y., Akashi, K., Maeda, T., & Ohno, Y. (2026). Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07196-6
Vancouver
Irifune H, Semba Y, Uehara Y, Ohta T, Sugio Y, Akashi K, et al. Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07196-6
BibTeX
@article{Irifune2026,
author = {Irifune, Hidetoshi and Semba, Yuichiro and Uehara, Yasufumi and Ohta, Takanori and Sugio, Yasuhiro and Akashi, Koichi and Maeda, Takahiro and Ohno, Yuju},
title = {Sequential emergence of FLT3-ITD and BCR::ABL1 during disease progression in relapsed acute myeloid leukemia},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07196-6}
}
EUVIMED